Status:
COMPLETED
Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the effect of repeated doses of the drug Lu AG06466 on the exposure of metoprolol, midazolam and bupropion
Detailed Description
On Day 1, midazolam and metoprolol will be dosed as an oral single-dose cocktail and PK sampling will be performed for 48 hours. On Day 3, bupropion will be dosed as a single oral dose and PK samplin...
Eligibility Criteria
Inclusion
- Body mass index (BMI) of 18.5 to 30 kg/m2 (inclusive) at the Screening and Baseline Visits
Exclusion
- The subject has any concurrent disorder that may affect the pharmacological target or absorption, distribution, or elimination of the investigational medicinal product.
- Other in- and exclusion criteria may apply
Key Trial Info
Start Date :
December 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 9 2021
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04713254
Start Date
December 8 2020
End Date
April 9 2021
Last Update
April 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Dallas CRU
Dallas, Texas, United States, 75247